Cenobamate - SK biopharmaceuticals
Alternative Names: ONO-2017; ONTOZRY; X-Copri; XCOPRI; YKP-3089Latest Information Update: 28 Jun 2024
At a glance
- Originator SK biopharmaceuticals
- Developer Angelini Pharmaceuticals; Arvelle Therapeutics; Endo Ventures; Ono Pharmaceutical; SK biopharmaceuticals; SK Life Science
- Class Analgesics; Antidepressants; Antiepileptic drugs; Anxiolytics; Carbamates; Chlorobenzenes; Mood stabilisers; Small molecules; Tetrazoles
- Mechanism of Action GABA A receptor modulators; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Partial epilepsies
- Phase III Tonic-clonic epilepsy
- Phase II Anxiety disorders; Bipolar disorders; Neuropathic pain
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Partial-epilepsies(Adjunctive treatment, In adolescents, In children, In adults) in USA (PO, Tablet)
- 13 Apr 2024 Pharmacokinetics and adverse event data from a phase I trial in Healthy volunteers presented at the76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
- 11 Apr 2024 US FDA approves cenobamate for alternate methods of administration for treatment of Partial epilepsies in USA